Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Daratumumab-Naïve Relapsed Multiple Myeloma: Multicenter Real-World Experience
- Resource Type
- Article
- Authors
- Mansour, Razan; Davis, James A; Minchak, Megan; Atallah, Rawan; Saif, Md Saiful Islam; Logan, Emerson; Tabak, Carine; Rashid, Aliya; Dima, Danai; Ahmed, Nausheen; Abdallah, Al-Ola; Hashmi, Hamza
- Source
- Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p3361-3361, 1p
- Subject
- Language
- ISSN
- 00064971; 15280020
Background:Daratumumab is an anti-CD38 monoclonal antibody approved in combination with pomalidomide/dexamethasone (DPd) and carfilzomib/dexamethasone (DKd) for patients with relapsed/refractory multiple myeloma (RRMM). We conducted a large multicenter retrospective study to analyze the safety and efficacy of DPd versus (vs) DKd in daratumumab naïve RRMM patients treated in real-world practice.